Paradiem LLC lessened its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 68.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,384 shares of the company’s stock after selling 17,792 shares during the quarter. Paradiem LLC’s holdings in Harmony Biosciences were worth $235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its stake in Harmony Biosciences by 589.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares in the last quarter. Allworth Financial LP lifted its stake in shares of Harmony Biosciences by 286.7% in the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after buying an additional 602 shares in the last quarter. Leonteq Securities AG bought a new position in shares of Harmony Biosciences in the fourth quarter worth approximately $30,000. National Bank of Canada FI purchased a new stake in shares of Harmony Biosciences during the third quarter valued at approximately $40,000. Finally, Clearstead Advisors LLC grew its holdings in shares of Harmony Biosciences by 145.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after buying an additional 699 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on HRMY shares. Truist Financial boosted their price objective on shares of Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a report on Friday, May 8th. Weiss Ratings upgraded Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, June 23rd. HC Wainwright restated a “buy” rating on shares of Harmony Biosciences in a research note on Wednesday, June 24th. Zacks Research raised Harmony Biosciences from a “strong sell” rating to a “hold” rating in a research report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Harmony Biosciences from $30.00 to $36.00 and gave the stock a “hold” rating in a report on Tuesday, June 30th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $42.50.
Harmony Biosciences Stock Performance
NASDAQ:HRMY opened at $36.84 on Monday. The company has a market cap of $2.13 billion, a PE ratio of 14.85, a price-to-earnings-growth ratio of 0.35 and a beta of 0.94. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. The company has a 50 day simple moving average of $33.19 and a two-hundred day simple moving average of $32.80. Harmony Biosciences Holdings, Inc. has a 12 month low of $25.52 and a 12 month high of $40.87.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The firm had revenue of $215.39 million for the quarter, compared to the consensus estimate of $220.84 million. During the same period in the previous year, the company earned $0.78 earnings per share. Harmony Biosciences’s quarterly revenue was up 16.6% compared to the same quarter last year. Research analysts forecast that Harmony Biosciences Holdings, Inc. will post 3.26 earnings per share for the current year.
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.
The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.
Further Reading
- Five stocks we like better than Harmony Biosciences
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
